QNRX — Quoin Pharmaceuticals, Ltd.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-07-29.
Performance
Technicals
Others in Healthcare
Measured signals that fired on QNRX
| date | signal | measured base rate |
|---|---|---|
| 2026-08-20 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2025-10-14 | LANGER DENNIS Director | Open-market purchase | 15.2K | 8.49 | 128.6K |
| 2024-12-23 | Myers Michael Chief Executive Officer | Open-market purchase | 555.6K | 0.45 | 250.0K |
| 2024-12-23 | Carter Denise P. Chief Operating Officer | Open-market purchase | 555.6K | 0.45 | 250.0K |
| 2024-12-23 | Dunn Gordon Chief Financial Officer | Open-market purchase | 122.2K | 0.45 | 55.0K |
| 2024-12-23 | Culverwell Anthony James Director | Open-market purchase | 100.0K | 0.45 | 45.0K |
| 2024-09-10 | Dunn Gordon Chief Financial Officer | Open-market purchase | 10.0K | 0.91 | 9.1K |
| 2024-09-10 | Dunn Gordon Chief Financial Officer | Open-market purchase | 10.0K | 0.71 | 7.1K |
| 2024-09-09 | Dunn Gordon Chief Financial Officer | Open-market purchase | 4.0K | 0.80 | 3.2K |
| 2024-09-09 | Dunn Gordon Chief Financial Officer | Open-market purchase | 4.0K | 0.78 | 3.1K |
| 2024-09-09 | Dunn Gordon Chief Financial Officer | Open-market purchase | 856 | 0.80 | 685 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Ikarian Capital, LLC | 1.4M | 211.5K |
| Dauntless Investment Group, LLC | 1.3M | 196.6K |
| SummitTX Capital, L.P. | 662.0K | 100.3K |
| Velan Capital Investment Management LP | 560.0K | 84.8K |
| Woodline Partners LP | 525.2K | 79.6K |
| MILLENNIUM MANAGEMENT LLC | 503.2K | 76.2K |
| Aberdeen Group plc | 495.0K | 75.0K |
| Soleus Capital Management, L.P. | 480.0K | 72.7K |
| Centiva Capital, LP | 396.0K | 60.0K |
| BOOTHBAY FUND MANAGEMENT, LLC | 394.9K | 59.8K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 8-K | 2026-08-14 | 2026-08-14 | on EDGAR ↗ |
| 10-Q | 2026-08-14 | 2026-06-30 | on EDGAR ↗ |
| ARS | 2026-07-16 | 2025-12-31 | on EDGAR ↗ |
| DEF 14A | 2026-07-16 | 2026-08-20 | on EDGAR ↗ |
| PRE 14A | 2026-07-06 | 2026-08-20 | on EDGAR ↗ |
| 8-K | 2026-06-23 | 2026-06-23 | on EDGAR ↗ |
| 8-K | 2026-06-04 | 2026-06-04 | on EDGAR ↗ |
| SCHEDULE 13G | 2026-06-02 | — | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Quoin Pharmaceuticals, Ltd. (QNRX) filed form 8-K · 2026-08-14 · SEC EDGAR
- Quoin Pharmaceuticals, Ltd. (QNRX) filed form 10-Q · 2026-08-14 · SEC EDGAR
Ask the AI about QNRX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →